| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -130,764 | -95,786 |
| Stock-based compensation expense | 9,298 | 5,582 |
| Prepaid expenses and other current assets | 12,836 | 6,346 |
| Accounts payable | 2,149 | 280 |
| Accrued expenses | 2,239 | 2,148 |
| Operating lease liabilities | -16 | -10 |
| Net cash used in operating activities | -129,930 | -94,132 |
| Purchase of short-term and long-term investments | 121,754 | 31,385 |
| Maturity of short-term and long-term investments | 121,725 | 82,116 |
| Net cash used in investing activities | -29 | 50,731 |
| Proceeds from issuance of common stock, net of issuance costs | 167,973 | - |
| Proceeds from the exercise of stock options | 418 | 369 |
| Payment of deferred financing costs | 53 | 353 |
| Proceeds from issuance of common stock in an initial public offering and atm facility, net of issuance costs | - | 81,857 |
| Net cash provided by financing activities | 168,338 | 81,873 |
| Net increase in cash and cash equivalents | 38,379 | 38,472 |
| Cash and cash equivalents at beginning of period | 74,293 | - |
| Cash and cash equivalents at end of period | 112,672 | - |
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)